Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The study investigates if CPX-351 will be a) more effective than the standard intensive
salvage AML treatment and b) more tolerable than the standard intensive salvage treatment
regimens.
The study compares the investigational product CPX-351 vs the standard intensive salvage
treatment for first relapse AML patients.